

REVIEW

Citicoline: neuroprotective mechanisms in cerebral ischemia

Rao Muralikrishna Adibhatla,*†‡ J. F. Hatcher* and R. J. Dempsey*†‡

*Department of Neurological Surgery and †Cardiovascular Research Center, University of Wisconsin, Madison, Wisconsin, USA

‡Veterans Administration Hospital, Madison, Wisconsin, USA

Abstract

Cytidine-5'-diphosphocholine (citicoline or CDP-choline), an intermediate in the biosynthesis of phosphatidylcholine (PtdCho), has shown beneficial effects in a number of CNS injury models and pathological conditions of the brain. Citicoline improved the outcome in several phase-III clinical trials of stroke, but provided inconclusive results in recent clinical trials. The therapeutic action of citicoline is thought to be caused by stimulation of PtdCho synthesis in the injured brain, although the experimental evidence for this is limited. This review attempts to shed some light on the properties of citicoline that are responsible for its effectiveness. Our studies in transient cerebral ischemia suggest that citicoline might enhance reconstruction (synthesis) of PtdCho and sphingomyelin, but could act by inhibiting the destructive processes (activation of phospholipases). Citicoline neuroprotection

may include: (i) preserving cardiolipin (an exclusive inner mitochondrial membrane component) and sphingomyelin; (ii) preserving the arachidonic acid content of PtdCho and phosphatidylethanolamine; (iii) partially restoring PtdCho levels; (iv) stimulating glutathione synthesis and glutathione reductase activity; (v) attenuating lipid peroxidation; and (vi) restoring Na⁺/K⁺-ATPase activity. These observed effects of citicoline could be explained by the attenuation of phospholipase A₂ activation. Based on these findings, a singular unifying mechanism has been hypothesized. Citicoline also provides choline for synthesis of neurotransmitter acetylcholine, stimulation of tyrosine hydroxylase activity and dopamine release.

Keywords: S-adenosyl-L-methionine, lipid peroxidation, mitochondria, phospholipases, phospholipids, stroke. *J. Neurochem.* (2002) **80**, 12–23.

Cytidine-5'-diphosphocholine (citicoline or CDP-choline) was originally identified as the intermediate in phosphatidylcholine (PtdCho) synthesis by Eugene Kennedy in 1956 (Kennedy and Weiss 1956). In 1983 22 articles were published that described the physico-chemical properties, pharmacokinetics, toxicity and bioavailability of this agent (Anonymous 1983). In 1995 there were two review articles that discussed the beneficial effects of this drug in CNS injury (Secades and Frontera 1995; Weiss 1995). Although much work has been carried out investigating citicoline absorption and metabolism, its mechanism of neuroprotection has not been experimentally delineated in CNS injury models including cerebral ischemia. Citicoline has shown beneficial effects in a variety of CNS injury models and neurodegenerative diseases, suggesting a common underlying mechanism associated with the loss of membrane integrity (Table 1). Citicoline neuroprotection is thought to be a result of increased PtdCho synthesis in the injured brain,

but the experimental evidence is limited. The present review takes an overview of citicoline neuroprotective actions based on our recent findings.

Received August 10, 2001; revised manuscript received September 28, 2001; accepted October 8, 2001.

Address correspondence and reprints to Dr Rao Muralikrishna Adibhatla, Department of Neurological Surgery, H4-330, Clinical Science Center, 600 Highland Avenue, University of Wisconsin-Madison, Madison, WI 53792–3232, USA. E-mail: adibhatl@neurosurg.wisc.edu


Abbreviations used: AdoMet, S-adenosyl-L-methionine; ArAc, arachidonic acid; citicoline, cytidine-5'-diphosphocholine; CMP, cytidine 5'-monophosphate; DAG, 1,2-diacylglycerol; GSH, glutathione (reduced); GSSG, glutathione (oxidized); nSMase, neutral sphingomyelinase; PCCT, cytidine triphosphate-phosphocholine cytidyltransferase; PtdCho, phosphatidylcholine; PtdEtn, phosphatidylethanolamine; PtdIns, phosphatidylinositol; PtdSer, phosphatidylserine; PLA₂, phospholipase A₂; PLC, phospholipase C; PLD, phospholipase D; ROS, reactive oxygen species; TBI, traumatic brain injury.

Table 1 Recent studies (since 1995) investigating the action of citicoline in neuropathological conditions

Study	Effect/Outcome	Reference
Transient forebrain ischemia/gerbil	Effects on lipids, phospholipases, glutathione, blood–brain barrier dysfunction, edema and neuronal death (details in Table 2)	(Adibhatla <i>et al.</i> 2001; Rao <i>et al.</i> 1999a,b, 2000a, 2001)
Transient middle cerebral artery occlusion/rat	Decreased edema and infarct volume Citicoline + basic fibroblast growth factor reduced infarct volume Citicoline + MK-801 reduced the infarct volume	(Schabitz <i>et al.</i> 1996) (Schabitz <i>et al.</i> 1999) (Onal <i>et al.</i> 1997)
Embolic focal cerebral ischemia/rat	Citicoline + rPA; promoted functional recovery and reduced infarction Citicoline and (citicoline + urokinase): improved neurobehavioral score and reduced infarct volume	(Andersen <i>et al.</i> 1999) (Shuaib <i>et al.</i> 2000)
Traumatic brain injury/rat	Improved cognitive deficits, increased acetylcholine levels Attenuated blood–brain barrier dysfunction and edema	(Dixon <i>et al.</i> 1997) (Baskaya <i>et al.</i> 2000)
Aged rats	Increased PCCT activity	(Gimenez <i>et al.</i> 1999)
Intracerebral hemorrhage/mice	Improved functional outcome, reduced ischemic injury volume and no effect on hematoma volume	(Clark <i>et al.</i> 1998)
β -amyloid deposit + hypoperfusion/rat	Attenuated hippocampal neuronal apoptosis and degeneration	(Alvarez <i>et al.</i> 1999)
Dog	Increased memory and learning	(Bruhwyler <i>et al.</i> 1998)
Clinical studies	Improved functional outcome and reduced neurological deficit in stroke patients Improved functional outcome in moderate-to-severe stroke patients Improved the neurological score No significant difference in lesion volume change with citicoline, determined by diffusion-weighted magnetic resonance imaging Improved memory performance in elderly subjects Improved mental performance in Alzheimer's disease	(Clark <i>et al.</i> 1997) (Clark <i>et al.</i> 1999) (Bruhwyler <i>et al.</i> 1997) (Warach <i>et al.</i> 2000) (Alvarez <i>et al.</i> 1997) (Cacabelos <i>et al.</i> 1996)

Citicoline metabolism

Citicoline is composed of two essential moieties, cytidine and choline, linked by a diphosphate bridge (Fig. 1), and serves as the phosphocholine donor to 1,2-diacylglycerol (DAG) to form PtdCho. Exogenous citicoline is hydrolyzed and absorbed as cytidine and choline (Secades and Frontera 1995; Weiss 1995). Following absorption, choline and cytidine are re-phosphorylated and citicoline is synthesized

**Fig. 1** Citicoline structure.

from cytidine triphosphate and choline monophosphate by cytidine triphosphate-phosphocholine cytidyl transferase (PCCT) (Fig. 2a) (Kent and Carman 1999). As the rate-limiting intermediate in PtdCho biosynthesis, it was believed that citicoline administration would provide benefit in pathological conditions such as CNS injury where membrane damage contributes to neuronal death.

During PtdCho synthesis, choline monophosphate is incorporated into PtdCho and cytidine 5'-monophosphate (CMP) is released. CMP can be utilized for synthesis of RNA, or of DNA as the deoxyribonucleotide. The choline moiety from citicoline can also be acetylated to the neurotransmitter acetylcholine, or metabolized to betaine, which serves as a source of methyl groups in the synthesis of methionine and *S*-adenosyl-L-methionine (AdoMet) (Fig. 2a). AdoMet is the methyl donor in the methylation of proteins and nucleotides, and the conversion of phosphatidyl-ethanolamine (PtdEtn) to PtdCho (Fig. 2a). The product *S*-adenosyl-L-homocysteine can be metabolized further to glutathione (GSH) (Adibhatla *et al.* 2001).

Pharmacokinetic studies have shown that orally administered citicoline is nearly completely absorbed with very little of the dose excreted (Agut *et al.* 1983). Brain uptake of

Loss of PtdCho and other membrane phospholipids caused by the stimulation of acetylcholine release implies that phospholipases are activated to release choline from PtdCho (and sphingomyelin). The specific phospholipases that are activated under these conditions have not been delineated (see the section entitled Phospholipases).

Citicoline was shown to stimulate tyrosine hydroxylase activity and dopamine release (Secades and Frontera 1995), which may be a result of increases in brain acetylcholine because choline administration also produced the same effects (Blusztajn and Wurtman 1983). Transient cerebral ischemia results in decreases in glucose utilization, acetylcholine synthesis (Kakihana *et al.* 1988) and choline acetyltransferase immunoreactivity (Ishimaru *et al.* 1994, 1995). Citicoline ameliorated the disruption of glucose metabolism, increased brain choline levels and stimulated acetylcholine synthesis (Kakihana *et al.* 1988).

Cerebral ischemia

Cerebral ischemia is caused by reduced blood supply to the brain and can be focal (regional) or global (forebrain). Energy failure, ATP loss, glutamate release and stimulation of glutamate receptors results in phospholipases activation (Siesjo 1992; Siesjo *et al.* 1995; Lipton 1999; Rao *et al.* 1999b), phospholipid hydrolysis and arachidonic acid (ArAc, 20 : 4) release (Rao *et al.* 1999c).

Interestingly, even though citicoline has undergone 12 clinical trials for the treatment of stroke, there have been no studies examining phospholipid changes including PtdCho or the effect of citicoline on lipid alterations in either permanent or transient *focal* ischemia models. There have been a number of studies conducted with citicoline in stroke models, showing a decrease in infarction volume or improvement in behavioral parameters (D'Orlando and Sandage 1995; Aronowski *et al.* 1996; Schabitz *et al.* 1996, 1999; Onal *et al.* 1997; Clark *et al.* 1998; Andersen *et al.* 1999; Shuaib *et al.* 2000) (Table 1), but no mechanistic data has been presented.

Phospholipids

Non-pathological conditions

Normal rats treated with citicoline (500 mg/kg per day) showed no significant increase in cortical PtdCho levels after 21 days of administration. PtdCho levels were significantly elevated (~22%) only after 42 days of treatment (Lopez-Coviella *et al.* 1995). This suggests that under non-pathological conditions, the synthesis of PtdCho is regulated to maintain normal brain levels.

Permanent global ischemia

Until recently only one paper had been published that examined the effects of citicoline on phospholipid changes in

cerebral ischemia (Trovarelli *et al.* 1981). This study was conducted in permanent ischemia (10-min global ischemia in gerbil with no reperfusion). Of the phospholipids examined, only PtdCho showed a significant decrease. Loss of ATP during ischemia results in the accumulation of CMP, which is normally phosphorylated to the triphosphate in the presence of ATP. It is generally believed that the accumulation of CMP contributes to PtdCho loss through reversal of the PtdCho synthesis pathway in the reaction (Dorman *et al.* 1983; Murphy and Horrocks 1993): $\text{CMP} + \text{PtdCho} \rightarrow \text{DAG} + \text{citicoline}$.

Intracerebroventricular injection of citicoline 5 min prior to ischemia partially but significantly restored PtdCho levels and decreased the release of free fatty acids. This effect was attributed to the stimulation of the choline phosphotransferase reaction to increase the incorporation of DAG into PtdCho. In these studies, citicoline was injected directly into the brain and thus cerebral levels of the drug were likely to be much higher than when the drug was administered systemically. Systemic pretreatment with citicoline (i.p.) did not significantly alter free fatty acid levels after 10 min of permanent ischemia (no reperfusion) in gerbil (Rao *et al.* 1999a).

Transient global ischemia

In 10-min transient forebrain ischemia in gerbil, hippocampal CA₁ neurons undergo delayed death beginning on day 3 and culminating on day 6 (Kirino and Sano 1984; Rao *et al.* 2000b). In our studies, one dose of citicoline administered at the onset of reperfusion did not show neuroprotection. Two doses at 0 and 3 h provided significant but incomplete neuroprotection (Rao *et al.* 1999b, 2001). Maximum neuroprotection was obtained when the treatments were continued over days 1–5 and neuronal survival was assessed on day 6 (Hatcher *et al.* 1999; Rao *et al.* 1999a).

Citicoline treatment attenuated ArAc release in hippocampus after 10-min forebrain ischemia/1-day reperfusion in gerbil (Rao *et al.* 1999a). Citicoline can decrease ArAc levels by either increasing the synthesis of PtdCho (Cui *et al.* 1996) or preventing the activation of phospholipase A₂ (PLA₂) (Arrigoni *et al.* 1987; Rao *et al.* 2001). Citicoline therefore may affect the levels of many lipids following ischemia and reperfusion. Whether citicoline directly inhibits PLA₂ or prevents its activation requires further investigation.

The 10-min ischemia with 0- (permanent ischemia) or 1-day reperfusion (transient ischemia) resulted in significant decreases in levels of PtdCho, PtdIns, PtdSer and sphingomyelin, but not PtdEtn (Rao *et al.* 2000a). ArAc levels also significantly decreased in PtdCho, PtdIns and PtdSer after ischemia/0-day reperfusion (permanent global ischemia), but not in PtdEtn.

In addition to these changes, there were significant decreases in cardiolipin and ArAc levels in PtdEtn following ischemia/1-day reperfusion (transient ischemia) (Rao *et al.*

2000a; Adibhatla *et al.* 2001). Citicoline significantly restored cardioliipin, sphingomyelin and both the ArAc levels and total fatty acids of PtdCho in 1-day reperfusion, but had no significant effect on the levels of PtdEtn, PtdIns or PtdSer. There were significant alterations in the composition of PtdCho and PtdEtn. Thus, although the total levels of PtdEtn fatty acids were unchanged following ischemia/1-day reperfusion, the ArAc content as a percentage of the total fatty acids showed a significant decline. This change in composition was observed also in PtdCho, in addition to the decrease in the level of total fatty acids. Treatment with citicoline significantly restored the ratio of ArAc to total fatty acids in both PtdCho and PtdEtn (Rao *et al.* 2000a).

The significant decrease in the levels of ArAc and the proportion of ArAc in total fatty acids in PtdEtn and PtdCho may be caused by the activation of PLA₂, which selectively hydrolyzes ArAc at the *sn*-2 position of PtdCho and PtdEtn (Rao *et al.* 2000a, 2001). The loss of PtdIns suggests the activation of a PtdIns-specific phospholipase C (PLC) (Rhee and Bae 1997). Both the total level of PtdCho and the ArAc content of PtdCho and PtdEtn, but not of PtdIns, were restored after ischemia/1-day reperfusion by the administration of citicoline. Citicoline could also have restored PtdCho levels by preventing the activation of PLA₂, which may account for the effect of citicoline on restoring the ArAc content of PtdEtn. The observation that citicoline did not restore PtdIns suggests it had no effect on PtdIns-PLC.

Citicoline may increase the level of PtdCho via two pathways: (Rao *et al.* 1999a) (i) transfer of phosphocholine to DAG in order to form PtdCho and (ii) choline liberated from citicoline can be utilized in biosynthesis of methionine and AdoMet (Fig. 2a). AdoMet serves as a methyl donor in the conversion of PtdEtn to PtdCho. Because PtdEtn contains a much higher proportion of docosahexaenoic acid (22 : 6, ~37% of total fatty acids) compared with PtdCho (4%), conversion of PtdEtn to PtdCho following citicoline treatment might be reflected in an increase in the 22 : 6 content of PtdCho. Citicoline did not alter the proportion of 22 : 6 in PtdCho, indicating that it did not significantly increase PtdEtn conversion to PtdCho (Rao *et al.* 2000a). These data are consistent with observations that PtdEtn-*N*-methyltransferase activity is high in liver, but is generally very low in other tissues (Walkey *et al.* 1998).

Cardiolipin

Cardiolipin is an exclusive inner mitochondrial phospholipid enriched with unsaturated fatty acids and is essential for mitochondrial electron transport (Hoch 1992). Citicoline prevented the loss of cardiolipin at 1-day reperfusion. The mechanism of cardiolipin degradation is not known at this time, although the involvement of PLA₂ has been suggested (Nakahara *et al.* 1991, 1992) (see the section entitled Phospholipases). It is conceivable that citicoline stimulated

cardiolipin synthesis by increasing cytidine diphosphodiacylglycerol, a precursor in the biosynthesis of both PtdIns and cardiolipin (Vance 1998). However, as citicoline treatment had no effect on PtdIns, it appears unlikely that citicoline increased biosynthesis of cytidine diphosphodiacylglycerol, and may therefore have prevented cardiolipin hydrolysis (Rao *et al.* 2001).

Sphingomyelin and ceramide

Citicoline completely restored sphingomyelin levels after ischemia/1-day reperfusion. Sphingomyelin can be synthesized using either PtdCho or citicoline as the phosphocholine donor to ceramide (Fig. 2b) (Stoffel and Melzner 1980; Vos *et al.* 1997; Goswami and Dawson 2000). Alternatively, sphingomyelinase is stimulated by tumor necrosis factor- α (Levade and Jaffrezou 1999; Liu *et al.* 1999), which is induced over a period of 1–6 h following transient forebrain ischemia (Saito *et al.* 1996). Activation of neutral sphingomyelinase may be mediated through PLA₂ and the release of ArAc (Jayadev *et al.* 1994). If citicoline modulates PLA₂ activity, activation of sphingomyelinase could in turn be affected.

Even though sphingomyelin levels declined following ischemia with no or 1-day reperfusion, the sphingomyelinase product ceramide did not show corresponding accumulation (Rao *et al.* 2000a). Ceramide levels may be highly regulated (Kolesnick and Fuks 1995), and further metabolism may preclude its accumulation. Alternatively, sphingomyelin might be hydrolyzed by a phospholipase that cleaves the fatty acid residue to form sphingosylphosphorylcholine (lysosphingomyelin) (Zeisel 1993). In contrast, ceramide levels were significantly elevated after 3 and 6 days of reperfusion, without a significant decrease in sphingomyelin, but it should be noted that the sphingomyelin pool is much larger than the levels of ceramide (Adibhatla *et al.* 2001). Although ceramide has been implicated in the induction of apoptosis (Green and Reed 1998; Goswami and Dawson 2000), its role in neuronal death remains debatable (Hofmann and Dixit 1998; Kolesnick and Hannun 1999). The increase in ceramide could be a signal of impending neuronal death (which begins after 3 days; Rao *et al.* 2000b) as apoptosis is usually accompanied by a late phase of ceramide production (Tepper *et al.* 2000). Ceramide levels further increased after 6 days and could be the result of neuronal death, which is nearly complete at this time. However, citicoline treatment did not alter ceramide levels on day 3 or day 6, even though it provided neuroprotection (Rao *et al.* 1999a), and thus ceramide levels did not correlate with neuronal death.

Under normal conditions plasma membrane phospholipids have an asymmetrical distribution: neutral phospholipids such as PtdCho and sphingomyelin are located in the exofacial membrane, whereas anionic phospholipids (PtdEtn, PtdIns and PtdSer) are localized in the cytofacial leaflet

(Devaux and Zachowski 1994; Wattiaux-De Coninck and Wattiaux 1994; Wood *et al.* 1996). Alterations of the plasma membrane structure caused by translocation of phospholipids between the exo- and cytofacial leaflets, a process known as phospholipid scrambling, induces apoptosis (Martin *et al.* 1995; Rimon *et al.* 1997; Suzuki *et al.* 1999; Kagan *et al.* 2000). Loss of sphingomyelin *per se* may contribute to membrane damage because it has a high affinity for cholesterol, and these lipids are major determinants of the membrane integrity. Sphingomyelin hydrolysis following phospholipid scrambling results in redistribution of cholesterol to intracellular compartments, causing major changes in membrane structure and fluidity (Tepper *et al.* 2000).

Phospholipases

PtdCho can be hydrolyzed (Exton 1994; Tronchere *et al.* 1994) by PtdCho-PLC (Li *et al.* 1998), PtdCho-phospholipase D (PLD) (Thompson *et al.* 1991, 1993; Klein *et al.* 1995), or PLA₂ (Farooqui *et al.* 1997a,b; Six and Dennis 2000). There is substantial evidence that PLA₂ is activated in ischemia/reperfusion and contributes to neuronal damage (Bonventre *et al.* 1997; Farooqui *et al.* 1999, 2000a,b,c; Rao *et al.* 1999c). PtdCho is hydrolyzed to provide choline to maintain neurotransmission when acetylcholine release is stimulated, but there is currently no clear evidence that PLA₂ is activated in response to the requirement for acetylcholine synthesis (see the Acetylcholine and Dopamine sections).

Our data on the effects of citicoline on phospholipids following transient ischemia are consistent with an effect on PLA₂ activation. However, there has been only *one* study (Arrigoni *et al.* 1987) directly examining the effect of citicoline on PLA₂, which demonstrated that citicoline prevented the increase in mitochondrial PLA₂ activity following cryogenic brain injury in rabbit, in which energy failure does not occur as it does in ischemia. It was concluded that citicoline prevented the activation of PLA₂ instead of directly inhibiting the enzyme as citicoline had no effect on PLA₂ activity in non-injured controls and restored PLA₂ activity to control levels in the injured group.

Previous studies have indicated that the mitochondrial PLA₂ is a Ca²⁺-dependent 14-kDa group IIA secretory PLA₂ (sPLA₂) isoform that acts on PtdCho, PtdEtn and cardiolipin (Nakahara *et al.* 1991, 1992; Rordorf *et al.* 1991; Zhang *et al.* 1999). It is possible that citicoline prevented the cardiolipin hydrolysis by inhibiting the activation of this isoform. Post-ischemic activation of a mitochondrial 14-kDa PLA₂ was demonstrated in transient forebrain ischemia in gerbil (Rordorf *et al.* 1991), but the effect of citicoline has not been determined. Our data also suggests that citicoline did not affect activities of phospholipase C or D because citicoline had no effect on PtdIns levels, and PtdCho levels were only partially restored (Rao *et al.* 2001).

Sustained activation of phospholipases over 7 days has been reported earlier in gerbil 5-min transient ischemia (Abe *et al.* 1989). However, our recent studies showed that all major phospholipids returned to sham levels after a 2–6-day reperfusion following 10-min ischemia (Adibhatla *et al.* 2001), suggesting that phospholipases are not significantly activated over this time. This is in agreement with previous studies which showed that phospholipases are down-regulated during this period (Lauritzen *et al.* 1994).

Lipid peroxidation and glutathione

Formation of reactive oxygen species (ROS) (including superoxide radical, hydrogen peroxide and hydroxyl radical) and the ensuing oxidation of biological molecules is a well-recognized mechanism of tissue damage in ischemia/reperfusion (Werns and Lucchesi 1990; Coyle and Puttfarcken 1993; Globus *et al.* 1995; Yamaguchi *et al.* 1998; Chan 2001). ROS induce lipid peroxidation, resulting in the formation of malondialdehyde and 4-hydroxynonenal (Esterbauer *et al.* 1991). 4-Hydroxynonenal induces neuronal apoptosis by covalently cross-linking with proteins (Uchida and Stadtman 1992; Kruman *et al.* 1997). One previous study showed that citicoline decreased lipid peroxidation following transient cerebral ischemia (Fresta *et al.* 1994), suggesting that citicoline neuroprotection may include the attenuation of oxygen radical formation.

Glutathione

Glutathione (GSH, reduced) is one of the primary endogenous antioxidant defense systems in the brain that removes hydrogen peroxide and lipid peroxides (Coyle and Puttfarcken 1993). Increased GSH may contribute to neuroprotection by attenuating lipid peroxidation (Rao *et al.* 2000a; Adibhatla *et al.* 2001). Choline liberated from citicoline can be metabolized to GSH through the AdoMet pathway (Fig. 2a). Exogenous AdoMet provided significant neuroprotection (Rao *et al.* 1997) and increased GSH levels (De la Cruz *et al.* 2000).

Total glutathione levels [GSH + glutathione (oxidized)] remained unaltered during 6-h reperfusion after ischemia, but decreased between 1 and 3 days. Several factors could contribute to this decrease, such as the cleavage of GSH to cysteine (Slivka and Cohen 1993), the decreased synthesis of GSH or the formation of mixed disulfides with GSSG (Shivakumar *et al.* 1995). Citicoline administration resulted in transient increases in total glutathione over 1-day reperfusion. Two considerations suggest these increases represent an increase in GSH synthesis (Lu 1999): GSSG levels were not altered during this time and the levels in citicoline treated groups exceeded sham levels. This suggests that citicoline did not simply prevent oxidation of GSH. Citicoline treatment beyond 1 day did not

significantly alter total glutathione levels (Adibhatla *et al.* 2001).

Changes in total glutathione represent alterations in GSH levels as GSSG levels accounted for only 2–4% of the total and showed very small changes (Adibhatla *et al.* 2001). Low levels of GSSG have been shown in other ischemia models, which were not altered during reperfusion (Cooper *et al.* 1980; Rehncrona *et al.* 1980). Citicoline treatment decreased the GSSG levels as well as the glutathione oxidation ratio ($2 \times \text{GSSG}/\text{total glutathione}$, an indicator of the redox status of glutathione), suggesting that citicoline attenuated the oxidative stress (Adibhatla *et al.* 2001).

Glutathione reductase

The activity of GSSG reductase decreases after transient ischemia (Shivakumar *et al.* 1995; Adibhatla *et al.* 2001). Loss of GSSG reductase activity may be a result of the inactivation of the enzyme by oxygen radicals generated during reperfusion (Chan *et al.* 1998). Changes in GSSG reductase activity were not accompanied by changes in GSSG levels, suggesting that either the reductase activity did not become limiting, or that excess GSSG was excreted or reacted with protein thiols to form mixed disulfides (Lu 1999). Administration of citicoline resulted in significant increases in reductase activity after transient ischemia. If the GSSG reductase is inactivated by ROS following ischemia, it is conceivable that citicoline prevented this inactivation by attenuating ROS formation.

Blood–brain barrier dysfunction and edema

Citicoline attenuated cerebral edema in transient focal (Schabitz *et al.* 1996) and global (Rao *et al.* 1999a,b) ischemia and traumatic brain injury (TBI) (Baskaya *et al.* 2000). Citicoline restored Na^+/K^+ -ATPase activity (following cold injury in rabbits) (Rigoulet *et al.* 1979) and thus may have attenuated cytotoxic edema. Because ArAc inhibits Na^+/K^+ -ATPase (Chan and Fishman 1978), restoration of this activity could be mediated through the prevention of PLA_2 activation and the subsequent decrease in ArAc release. Alternatively, citicoline had a direct stimulatory effect on Na^+/K^+ -ATPase activity *in vitro* (Plataras *et al.* 2000). Citicoline also attenuated blood–brain barrier dysfunction following TBI (Baskaya *et al.* 2000) or transient forebrain ischemia (Rao *et al.* 1999a) thus attenuating vasogenic edema.

The known effects of citicoline, to the best of our knowledge are summarized in Table 2. Many of the effects of citicoline could be explained by the attenuation of PLA_2 activation (Fig. 3). If citicoline primarily acts by preventing PLA_2 activation, the effects of citicoline may be limited to those cell types wherein PLA_2 is activated. *In situ* hybridization studies indicated that the expression of cytosolic PLA_2 (Kishimoto *et al.* 1999) and type-II $s\text{PLA}_2$ (Lauritzen *et al.* 1994) in the hippocampus was primarily neuronal. To the best of our knowledge virtually no literature exists on lipid alterations or the biochemical actions/mechanisms of citicoline in focal cerebral injury. One of the common

Table 2 Citicoline mechanisms of action

Function/System	Action	Reference
Lipids		
Affected	Restored cardiolipin and sphingomyelin levels	(Rao <i>et al.</i> 2000a)
	Partially restored PtdCho	(Rao <i>et al.</i> 2000a)
	ArAc composition of PtdCho and PtdEtn	(Rao <i>et al.</i> 2000a)
	ArAc release	(Rao <i>et al.</i> 1999a; Trovarelli <i>et al.</i> 1981)
	Leukotriene C ₄ formation	(Rao <i>et al.</i> 1999a)
Unaffected	PtdSer, PtdIns and ceramide	(Rao <i>et al.</i> 2000a)
	Methylation of PtdEtn to PtdCho	(Rao <i>et al.</i> 2000a)
Phospholipases:	Affecting the activation of PLA_2	(Arrigoni <i>et al.</i> 1987; Rao <i>et al.</i> 2001)
	May not affect PLC and PLD	(Rao <i>et al.</i> 2001)
Antioxidant systems:	Increase GSH levels and GSSG reductase activity	(Adibhatla <i>et al.</i> 2001)
	Attenuated glutathione oxidation ratio	(Adibhatla <i>et al.</i> 2001)
	Attenuated lipid peroxidation	(Fresta and Puglisi 1996; Fresta <i>et al.</i> 1994)
Neurotransmitter systems:	Increase in acetylcholine synthesis	(Kakahana <i>et al.</i> 1988; Dixon <i>et al.</i> 1997)
	Increase in tyrosine hydroxylase activity and dopamine levels	(Secades and Frontera 1995)
Ion transport:	Restored Na^+/K^+ -ATPase activity	(Rigoulet <i>et al.</i> 1979)
Physiological:	Decreased edema	(Baskaya <i>et al.</i> 2000; Rao <i>et al.</i> 1999a; Schabitz <i>et al.</i> 1996)
	Attenuated blood–brain barrier dysfunction	(Baskaya <i>et al.</i> 2000; Rao <i>et al.</i> 1999a)




Fig. 3 Proposed major pathway of citicoline neuroprotection. ArAc, arachidonic acid; GSH, glutathione; nSMase, neutral sphingomyelinase; PLA₂ phospholipase A₂; PtdCho, phosphatidylcholine; ROS, reactive oxygen species. ↑ indicates increase; ↓ indicates decrease.

features of cerebral ischemia, whether global or focal, is energy failure and activation of phospholipases (Siesjo 1992; Siesjo *et al.* 1995). Thus, the effects of citicoline on PLA₂ activation may be applicable to focal ischemia models also. This hypothesized singular unifying mechanism (Fig. 3) needs to be investigated further.

Current status in clinical trials

Of the neuroprotective agents undergoing phase-III clinical trials in acute stroke (De Keyser *et al.* 1999; Fisher and Schaebitz 2000), citicoline has shown beneficial effects with virtually no side-effects, whereas all the other treatments have given negative results with regard to the primary outcome (functional and/or cognitive) measure (Clark *et al.* 1999; De Keyser *et al.* 1999; STAIR-II 2001). However, the most recent clinical trials of citicoline did not provide conclusive results.

There have been 12 clinical trials of citicoline since 1980 (nine in Europe and Japan and three in the USA) (Boudouresques and Michel 1980; Goyas *et al.* 1980; Hazama *et al.* 1980; Corso *et al.* 1982; Franceschi *et al.* 1982; Tazaki *et al.* 1988; Bruhwyler *et al.* 1997; Clark *et al.* 1997, 1999; Warach *et al.* 2000). The European clinical trials showed that citicoline improved global and neurological function and promoted earlier motor and cognitive recovery. A large multicenter study in Japan found that citicoline showed improvement in the global outcome rating scale (Tazaki *et al.* 1988). Three major clinical trials in the USA were conducted in 1997 (Clark *et al.* 1997), 1999 (Clark *et al.* 1999) and 2000 (Warach *et al.* 2000). In the first study, 259 patients were enrolled with citicoline treatment initiated within 24 h of stroke onset (mean time to treatment was 14.5 h). Citicoline improved the functional outcome and reduced the neurologic deficit with 500 mg appearing to be the optimal dose. However, the second study involving 394

patients (Clark *et al.* 1999) failed to demonstrate improvement in the outcome. In *post-hoc* analysis, citicoline was shown to provide beneficial effects in a subgroup of moderate–severe stroke cases (Clark *et al.* 1999). In the third study (Warach *et al.* 2000), although a large difference in the percentage change in lesion volume was observed in favor of citicoline (34% for citicoline vs. 180% for placebo group), the large variance in the placebo group precluded statistical significance. Owing to the inconclusive results of some of the clinical trials, further studies are necessary to obtain clear results on the efficacy of citicoline for stroke therapy.

Although citicoline clinical trials were initiated based on the positive outcome in animal models, a recent study showed that citicoline metabolism in humans (Wurtman *et al.* 2000) differs from that in rodents (Lopez-Coviella *et al.* 1995). In rodents, blood plasma levels of cytidine and choline are increased after oral citicoline (Lopez-Coviella *et al.* 1995). However, in humans blood plasma levels of uridine, but not cytidine, are increased after oral citicoline as a result of cytidine deaminase in the gastrointestinal tract and liver (Wurtman *et al.* 2000). Uridine must then enter the brain, become phosphorylated to uridine triphosphate, which in turn is converted to cytidine triphosphate.

As a result of the multiple pathways involved in ischemic injury, no single agent is likely to provide complete neuroprotection following transient ischemia (White *et al.* 2000). Citicoline restored cardiolipin and sphingomyelin, partially restored PtdCho, and completely restored the ArAc composition of PtdCho and PtdEtn, which would help stabilize the cellular membrane and restore mitochondrial function. Citicoline also decreased lipid peroxidation and increased GSH. It is likely that all of these effects contribute to citicoline neuroprotection as there is substantial evidence that loss of phospholipids (Siesjo and Katsura 1992; Siesjo *et al.* 1995; Farooqui *et al.* 1997a,b; Rao *et al.* 1999b) and generation of ROS (Siesjo *et al.* 1989; Chan 2001) contribute to ischemic injury. Citicoline had no effect on cytofacial phospholipids (PtdIns or PtdSer), and did not fully prevent the loss of PtdCho. Thus, its ability to completely restore membrane integrity may be limited. Most of the observed biochemical consequences could be attributable to the inhibition of PLA₂ activation (Fig. 3).

Combining agents with different mechanisms of action will probably be necessary for full recovery (De Keyser *et al.* 1999). Citicoline in combination with NMDA receptor antagonist MK801 (Onal *et al.* 1997), thrombolytic agents (recombinant tissue plasminogen activator) (Andersen *et al.* 1999) or urokinase (Shuaib *et al.* 2000), or basic fibroblast growth factor (Schabitz *et al.* 1999) showed synergistic benefit in experimental ischemia models. Identifying the mechanism(s) by which citicoline provides neuroprotection is crucial to develop more efficient treatment strategies for stroke.

Acknowledgements

This study was supported by start-up funding and a Medical School Research grant (161–9904) from the University of Wisconsin to RMA. We dedicate this review to Prof. Eugene Kennedy ‘the father of the CDP-choline pathway’.

Note added in proof

Recently it has been shown that the other hydrolysis product of PtdCho by PLA₂, lyso-PtdCho could inhibit the PCCT activity (Boggs *et al.* 1995; Awasati *et al.* 2001) resulting in impairment of PtdCho synthesis. Citicoline may increase PCCT activity (Gimenez *et al.* 1999) by inhibiting PLA₂ activation and limiting the formation of lyso-PtdCho.

References

- Abe K., Yoshidomi M. and Kogure K. (1989) Arachidonic acid metabolism in ischemic neuronal damage. *Ann. NY Acad. Sci.* **559**, 259–268.
- Adibhatla R. M., Hatcher J. F. and Dempsey R. J. (2001) Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. *Stroke* **32**, 2376–2381.
- Agut J., Font E., Sacristan A. and Ortiz J. A. (1983) Bioavailability of methyl-¹⁴C CDP-choline by oral route. *Arzneim.-Forsch.* **33**, 1045–1047.
- Alvarez X. A., Laredo M., Corzo D., Fernandez-Novoa L., Mouzo R., Perea J. E., Daniele D. and Cacabelos R. (1997) Citicoline improves memory performance in elderly subjects. *Methods Find. Exp. Clin. Pharmacol.* **19**, 201–210.
- Alvarez X. A., Sampedro C., Lozano R. and Cacabelos R. (1999) Citicoline protects hippocampal neurons against apoptosis induced by brain β -amyloid deposits plus cerebral hypoperfusion in rats. *Meth. Find. Exp. Clin. Pharmacol.* **21**, 535–540.
- Andersen M., Overgaard K., Meden P. and Boysen G. (1999) Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. *Stroke* **30**, 1464–1470.
- Anonymous (1983) Cytidine diphosphate choline (citicoline, Somazina). *Arzneim.-Forsch.* **33**, 1011–1080.
- Aronowski J., Strong R. and Grotta J. C. (1996) Citicoline for treatment of experimental focal ischemia: histologic and behavioral outcome. *Neurol. Res.* **18**, 570–574.
- Arrigoni E., Averet N. and Cohadon F. (1987) Effects of CDP-choline on phospholipase A₂ and cholinephosphotransferase activities following a cryogenic brain injury in the rabbit. *Biochem. Pharmacol.* **36**, 3697–3700.
- Awasthi S., Vivekananda J., Awasthi V., Smith D. and King R. J. (2001) CTP:phosphocholine cytidyltransferase inhibition by ceramide via PKC- α , p38 MAPK, cPLA₂, and 5-lipoxygenase. *Am. J. Physiol.* **281**, L108–L118.
- Baskaya M. K., Dogan A., Rao A. M. and Dempsey R. J. (2000) Neuroprotective effects of citicoline on brain edema and blood–brain barrier breakdown after traumatic brain injury. *J. Neurosurg.* **92**, 448–452.
- Blusztajn J. K. and Wurtman R. J. (1983) Choline and cholinergic neurons. *Science* **221**, 614–620.
- Boggs K. P., Rock C. O. and Jackowski S. (1995) Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-*rac*-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP-phosphocholine cytidyltransferase step. *J. Biol. Chem.* **270**, 7757–7764.
- Bonventre J. V., Huang Z. H., Taheri M. R., O’leary E., Li E., Moskowitz M. A. and Sapirstein A. (1997) Reduced fertility and postischemic brain injury in mice deficient in cytosolic phospholipase A₂. *Nature* **390**, 622–625.
- Boudouresques A. B. and Michel B. (1980) Therapeutic conduct in light of a cerebral vascular accident and the use of CDP-choline. *International Symposium, Brain Suffering and Precursors of Phospholipids*. Paris, Jan 18, 1980, 109–121.
- Bruhwyler J., Vandorpe J. and Geczy J. (1997) Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction. *Curr. Therap. Res. Clin. Exptl* **58**, 309–316.
- Bruhwyler J., Liegeois J. F. and Geczy J. (1998) Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog. *Prog. Neuro.-Psychopharm. Biol. Psych.* **22**, 115–128.
- Cacabelos R., Caamano J., Gomez M. J., Fernandez-Novoa L., Franco-Maside A. and Alvarez X. A. (1996) Therapeutic effects of CDP-choline in Alzheimer’s disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. *Ann. NY Acad. Sci.* **777**, 399–403.
- Chan P. H. (2001) Reactive oxygen radicals in signaling and damage in the ischemic brain. *J. Cereb. Blood Flow Metab.* **21**, 2–14.
- Chan P. H. and Fishman R. A. (1978) Brain edema: Induction in cortical slices by polyunsaturated fatty acids. *Science* **201**, 358–360.
- Chan P. H., Kawase M., Murakami K., Chen S. F., Li Y., Calagui B., Reola L., Carlson E. and Epstein C. J. (1998) Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischemia and reperfusion. *J. Neurosci.* **18**, 8292–8299.
- Clark W. M., Warach S. J., Pettigrew L. C., Gammans R. E. and Sabounjian L. A. (1997) A randomized dose–response trial of citicoline in acute ischemic stroke patients. *Stroke* **49**, 671–678.
- Clark W., Gunionrinker L., Lessov N. and Hazel K. (1998) Citicoline treatment for experimental intracerebral hemorrhage in mice. *Stroke* **29**, 2136–2139.
- Clark W. M., Williams B. J., Selzer K. A., Zweifler R. M., Sabounjian L. A. and Gammans R. E. (1999) A randomized efficacy trial of citicoline in patients with acute ischemic stroke. *Stroke* **30**, 2592–2597.
- Cooper A. J., Pulsinelli W. A. and Duffy T. E. (1980) Glutathione and ascorbate during ischemia and postischemic reperfusion in rat brain. *J. Neurochem.* **35**, 1242–1245.
- Corso A., Arena M., Ventimiglia A., Bizzarro G., Campo G. and Radalica F. (1982) CDP-choline for cerebrovascular disorders: clinical evaluation and evaluation of electrophysiological symptomatology (Italian). *Clini. Ter* **102**, 379–386.
- Coyle J. T. and Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. *Science* **262**, 689–695.
- Cui Z., Houweling M., Chen M. H., Record M., Chap H., Vance D. E. and Terce F. (1996) A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in chinese hamster ovary cells. *J. Biol. Chem.* **271**, 14668–14671.
- D’Orlando K. J. and Sandage B. W. Jr (1995) Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. *Neurol. Res.* **17**, 281–284.
- De Keyser J., Sulter G. and Luiten P. G. (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? *Trends Neurosci.* **22**, 535–540.
- De la Cruz J. P., Pavia J., Gonzalez-Correa J. A., Ortiz P. and de la Cuesta F. S. (2000) Effects of chronic administration of S-adenosyl-1-methionine on brain oxidative stress in rats. *Arch. Pharmacol.* **361**, 47–52.
- Devaux P. F. and Zachowski A. (1994) Maintenance and consequences of membrane phospholipid asymmetry. *Chem. Phys. Lipids* **73**, 107–120.

- Dixon C. E., Ma X. C. and Marion D. W. (1997) Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. *J. Neurotrauma* **14**, 161–169.
- Dorman R. V., Dabrowiecki Z. and Horrocks L. A. (1983) Effects of CDP-choline and CDP-ethanolamine on the alterations in rat brain lipid metabolism induced by global ischemia. *J. Neurochem.* **40**, 276–279.
- Esterbauer H., Schaur R. J. and Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Rad. Biol. Med.* **11**, 81–128.
- Exton J. H. (1994) Phosphatidylcholine breakdown and signal transduction. *Biochim. Biophys. Acta* **1212**, 26–42.
- Farooqui A. A., Yang H. C. and Horrocks L. (1997a) Involvement of phospholipase A₂ in neurodegeneration. *Neurochem. Int.* **30**, 517–522.
- Farooqui A. A., Yang H. C., Rosenberger T. A. and Horrocks L. A. (1997b) Phospholipase A₂ and its role in brain tissue. *J. Neurochem.* **69**, 889–901.
- Farooqui A. A., Litsky M. L., Farooqui T. and Horrocks L. A. (1999) Inhibitors of intracellular phospholipase A (2) activity: Their neurochemical effects and therapeutic importance for neurological disorders. *Brain Res. Bull.* **49**, 139–153.
- Farooqui A. A., Horrocks L. A. and Farooqui T. (2000a) Deacylation and reacylation of neural membrane glycerophospholipids – A matter of life and death. *J. Mol. Neurosci.* **14**, 123–135.
- Farooqui A. A., Horrocks L. A. and Farooqui T. (2000b) Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. *Chem. Phys. Lipids* **106**, 1–29.
- Farooqui A. A., Ong W. Y. and Horrocks L. A. (2000c) Brain cytosolic phospholipase A₂: localization, role, and involvement in neurological diseases. *Neuroscientist* **6**, 169–180.
- Fisher M. and Schaebitz W. (2000) An overview of acute stroke therapy: past, present, and future. *Arch. Int. Med.* **160**, 3196–3206.
- Franceschi M., Smirne S. and Canal N. (1982) Treatment of clinical signs and EEG patterns in patients with 'organic brain syndrome. Effect of citidine-diphosphocholine, citicholine. *Clin. Trials J.* **19**, 74–84.
- Fresta M. and Puglisi G. (1996) Biological effects of CDP-choline loaded long circulating liposomes on rat cerebral post-ischemic reperfusion. *Int. J. Pharm.* **134**, 89–97.
- Fresta M. and Puglisi G. (1997) Survival rate improvement in a rat ischemia model by long circulating liposomes containing cytidine-5-diphosphate choline. *Life Sci.* **61**, 1227–1235.
- Fresta M. and Puglisi G. (1999) Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes. *Pharm. Res.* **16**, 1843–1849.
- Fresta M., Puglisi G., Giacomini C. D. and Russo A. (1994) Liposomes as in vivo carriers for citicoline: effects on rat cerebral post-ischemic reperfusion. *J. Pharm. Pharmacol.* **46**, 974–981.
- Fresta M., Wehrli E. and Puglisi G. (1995) Enhanced therapeutic effect of cytidine-5'-diphosphate choline when associated with G (M1) containing small liposomes as demonstrated in a rat ischemia model. *Pharm. Res.* **12**, 1769–1774.
- Galletti P., De Rosa M., Cotticelli M. G., Morana A., Vaccaro R. and Zappia V. (1991) Biochemical rationale for the use of CDP-choline in traumatic brain injury: pharmacokinetics of the orally administered drug. *J. Neurol. Sci.* **103**, S19–S25.
- Gimenez R., Soler S. and Aguilar J. (1999) Cytidine diphosphate choline administration activates brain cytidine triphosphate: phosphocholine cytidyltransferase in aged rats. *Neurosci. Lett.* **273**, 163–166.
- Globus M. Y. T., Busto R., Lin B., Schnippering H. and Ginsberg M. D. (1995) Detection of free radical activity during transient global ischemia and recirculation: effects of intras ischemic brain temperature modulation. *J. Neurochem.* **65**, 1250–1256.
- Goswami R. and Dawson G. (2000) Does ceramide play a role in neural cell apoptosis? *J. Neurosci. Res.* **60**, 141–149.
- Goyas J. Y., Bastard J. and Missoum A. (1980) Results after 90 days of stroke treatment with CDP-choline, concerning a double blind test. *International Symposium, Brain Suffering and Precursors of Phospholipids*. Paris, Jan 18, 1980, 123–128.
- Green D. R. and Reed J. C. (1998) Mitochondria and apoptosis. *Science* **281**, 1309–1312.
- Hatcher J. F., Dempsey R. J. and Rao A. M. (1999) Ischemic severity and neuroprotection by CDP-choline: #236.4. *Soc. Neurosci. Abstract.* **25**, 583.
- Hazama T., Hasegawa T., Ueda S. and Sakuma A. (1980) Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial: Assessed by a new rating scale for recovery in hemiplegia. *Int. J. Neurosci.* **11**, 211–215.
- Hoch F. L. (1992) Cardiolipins and biomembrane function. *Biochim. Biophys. Acta* **1113**, 71–133.
- Hofmann K. and Dixit V. M. (1998) Ceramide in apoptosis – does it really matter? *Trends Biochem. Sci.* **23**, 374–377.
- Ishimaru H., Takahashi A., Ikarashi Y. and Maruyama Y. (1994) Effect of transient cerebral ischaemia on acetylcholine release in the gerbil hippocampus. *Neuroreport* **5**, 601–604.
- Ishimaru H., Takahashi A., Ikarashi Y. and Maruyama Y. (1995) Immunohistochemical and neurochemical studies of hippocampal cholinergic neurones after ischaemia. *Neuroreport* **6**, 557–560.
- Jayadev S., Linardic C. M. and Hannun Y. A. (1994) Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor- α . *J. Biol. Chem.* **269**, 5757–5763.
- Kagan V. E., Fabisiak J. P., Shvedova A. A., Tyurina Y. Y., Tyurin V. A., Schor N. F. and Kawai K. (2000) Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis. *FEBS Lett.* **477**, 1–7.
- Kakahana M., Fukuda N., Suno M. and Nagaoka A. (1988) Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. *Stroke* **19**, 217–222.
- Kennedy E. P. and Weiss S. B. (1956) The function of cytidine coenzymes in the biosynthesis of phospholipids. *J. Biol. Chem.* **222**, 193–214.
- Kent C. and Carman G. M. (1999) Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. *Trends Biochem. Sci.* **24**, 146–150.
- Kirino T. and Sano K. (1984) Selective vulnerability in the gerbil hippocampus following transient ischemia. *Acta Neuropathol.* **62**, 201–208.
- Kishimoto K., Matsumura K., Kataoka Y., Morii H. and Watanabe Y. (1999) Localization of cytosolic phospholipase A₂ messenger RNA mainly in neurons in the rat brain. *Neuroscience* **92**, 1061–1077.
- Klein J. (2000) Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. *J. Neur. Tran.* **107**, 1027–1063.
- Klein J., Chalifa V., Liscovitch M. and Loffelholz K. (1995) Role of phospholipase D activation in nervous system physiology and pathophysiology. *J. Neurochem.* **65**, 1445–1455.
- Kolesnick R. and Fuks Z. (1995) Ceramide: a signal for apoptosis or mitogenesis? *J. Exp. Med.* **181**, 1949–1952.
- Kolesnick R. and Hannun Y. A. (1999) Ceramide and apoptosis. *Trends Biochem. Sci.* **24**, 224–225.
- Kruman I., Brucekeller A. J., Bredesen D., Waeg G. and Mattson M. P. (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. *J. Neurosci.* **17**, 5089–5100.
- Lauritzen I., Heurteaux C. and Lazdunski M. (1994) Expression of group II phospholipase A₂ in rat brain after severe forebrain ischemia and in endotoxic shock. *Brain Res.* **651**, 353–356.

- Levade T. and Jaffrezou J. P. (1999) Signalling sphingomyelinases: which, where, how and why? *Biochim. Biophys. Acta* **1438**, 1–17.
- Li Y. H., Maher P. and Schubert D. (1998) Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. *Proc. Natl Acad. Sci. USA* **95**, 7748–7753.
- Lipton P. (1999) Ischemic cell death in brain neurons. *Physiol. Rev.* **79**, 1431–1568.
- Liu G. L., Kleine L. and Hebert R. L. (1999) Advances in the signal transduction of ceramide and related sphingolipids. *Crit. Rev. Clin. Lab. Sci.* **36**, 511–573.
- Lopez-Coviella I., Agut J., Savci V., Ortiz J. A. and Wurtman R. J. (1995) Evidence that 5'-cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels. *J. Neurochem.* **65**, 889–894.
- Lu S. C. (1999) Regulation of hepatic glutathione synthesis: current concepts and controversies. *FASEB J.* **13**, 1169–1183.
- Martin S. J., Reutelingsperger C. P. M., McGahon A. J., Rader J. A., Vanschie R., Laface D. M. and Green D. R. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus – inhibition by overexpression of bcl-2 and abl. *J. Exp. Med.* **182**, 1545–1556.
- Murphy E. J. and Horrocks L. A. (1993) CDP-choline, CDP-ethanolamine, lipid metabolism and disorders of the central nervous system, in *Phospholipids and Signal Transmission*, Vol. H70: *NATO ASI Series*, (Massarelli R., Horrocks L. A., Kanfer J. N. and Loffelholz K., eds) pp. 353–372. Springer-Verlag, Berlin Heidelberg.
- Nakahara I., Kikuchi H., Taki W., Nishi S., Kito M., Yonekawa Y., Goto Y. and Ogata N. (1991) Degradation of mitochondrial phospholipids during experimental cerebral ischemia in rats. *J. Neurochem.* **57**, 839–844.
- Nakahara I., Kikuchi H., Taki W., Nishi S., Kito M., Yonekawa Y., Goto Y. and Ogata N. (1992) Changes in major phospholipids of mitochondria during postischemic reperfusion in rat brain. *J. Neurosurg.* **76**, 244–250.
- Onal M. Z., Li F. H., Tatlisumak T., Locke K. W., Sandage B. W. and Fisher M. (1997) Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. *Stroke* **28**, 1060–1065.
- Plataras C., Tsakiris S. and Angelogianni P. (2000) Effect of CDP-choline on brain acetylcholinesterase and Na⁺,K⁺-ATPase in adult rats. *Clin. Biochem.* **33**, 351–357.
- Rao A. M., Baskaya M. K., Maley M. E., Kindy M. S. and Dempsey R. J. (1997) Beneficial effects of S-adenosyl-L-methionine on blood-brain barrier breakdown and neuronal survival after transient cerebral ischemia in gerbils. *Mol. Brain Res.* **44**, 134–138.
- Rao A. M., Hatcher J. F. and Dempsey R. J. (1999a) CDP-choline: neuroprotection in transient forebrain ischemia of gerbils. *J. Neurosci. Res.* **58**, 697–705.
- Rao A. M., Hatcher J. F. and Dempsey R. J. (1999b) Lipid metabolism in ischemic neuronal death. *Rec. Res. Dev. Neurochem.* **2**, 533–549.
- Rao A. M., Hatcher J. F., Kindy M. S. and Dempsey R. J. (1999c) Arachidonic acid and leukotriene C₄: Role in transient cerebral ischemia of gerbils. *Neurochem. Res.* **24**, 1225–1232.
- Rao A. M., Hatcher J. F. and Dempsey R. J. (2000a) Lipid alterations in transient forebrain ischemia: possible new mechanisms of CDP-choline neuroprotection. *J. Neurochem.* **75**, 2528–2535.
- Rao V. L. R., Rao A. M., Dogan A., Bowen K. K., Hatcher J. F., Rothstein J. D. and Dempsey R. J. (2000b) Glial glutamate transporter GLT-1 down-regulation precedes delayed neuronal death in gerbil hippocampus following transient global cerebral ischemia. *Neurochem. Int.* **36**, 531–537.
- Rao A. M., Hatcher J. F. and Dempsey R. J. (2001) Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? *Brain Res.* **893**, 268–272.
- Rehncrona S., Folbergrova J., Smith D. S. and Siesjo B. K. (1980) Influence of complete and pronounced incomplete cerebral ischemia and subsequent recirculation on cortical concentrations of oxidized and reduced glutathione in the rat. *J. Neurochem.* **34**, 477–486.
- Rhee S. G. and Bae Y. S. (1997) Regulation of phosphoinositide-specific phospholipase C isozymes. *J. Biol. Chem.* **272**, 15045–15048.
- Rigoulet M., Guerin B., Cohadon F. and Vandendriessche M. (1979) Unilateral brain injury in the rabbit: reversible and irreversible damage of the membranous ATPases. *J. Neurochem.* **32**, 535–541.
- Rimon G., Bazenet C. E., Philpott K. L. and Rubin L. L. (1997) Increased surface phosphatidylserine is an early marker of neuronal apoptosis. *J. Neurosci. Res.* **48**, 563–570.
- Rordorf G., Uemura Y. and Bonventre J. V. (1991) Characterization of phospholipase A₂ (PLA₂) activity in gerbil brain: enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion. *J. Neurosci.* **11**, 1829–1836.
- Saito K., Suyama K., Nishida K., Sei Y. and Basile A. S. (1996) Early increases in TNF- α , IL-6 and IL-1 β levels following transient cerebral ischemia in gerbil brain. *Neurosci. Lett.* **206**, 149–152.
- Schabitz W. R., Weber J., Takano K., Sandage B. W., Locker K. W. and Fisher M. (1996) The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. *J. Neurol. Sci.* **138**, 21–25.
- Schabitz W. R., Li F., Katsumi I., Sandage B. W., Locke K. W. and Fischer M. (1999) Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia. *Stroke* **30**, 427–432.
- Secades J. J. and Frontera G. (1995) CDP-choline: pharmacological and clinical review. *Meth. Find. Exp. Clin. Pharmacol.* **17**, 2–54.
- Shivakumar B. R., Kolluri S. V. and Ravindranath V. (1995) Glutathione and protein thiol homeostasis in brain during reperfusion after cerebral ischemia. *J. Pharmacol. Exp. Therap.* **274**, 1167–1173.
- Shuaib A., Yang Y. and Li Q. (2000) Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase. *Exp. Neurol.* **161**, 733–739.
- Siesjo B. K. (1992) Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. *J. Neurosurg.* **77**, 337–354.
- Siesjo B. K. and Katsura K. (1992) Ischemic brain damage: focus on lipids and lipid mediators. *Adv. Exp. Med. Biol.* **318**, 41–56.
- Siesjo B. K., Agardh C. and Bengtsson F. (1989) Free radicals and brain damage. *Cerebrovasc. Brain Metab. Rev.* **1**, 165–211.
- Siesjo B. K., Katsura K., Zhao Q., Folbergrova J., Pahlmark K., Siesjo P. and Smith M. L. (1995) Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. *J. Neurotrauma* **12**, 943–956.
- Six D. A. and Dennis E. A. (2000) The expanding superfamily of phospholipase A (2) enzymes: classification and characterization. *Biochim. Biophys. Acta. Mol. Cell Biol. Lipids* **1488**, 1–19.
- Slivka A. and Cohen G. (1993) Brain ischemia markedly elevates levels of the neurotoxic amino acid, cysteine. *Brain Res.* **608**, 33–37.
- STAIR-II (2001) Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies. *Stroke* **32**, 1598–1606.
- Stoffel W. and Melzner I. (1980) Studies in vitro on the biosynthesis of ceramide and sphingomyelin. A reevaluation of proposed pathways. *Z. Physiol. Chem.* **361**, 755–771.
- Suzuki S., Furushiro M., Takahashi M., Sakai M. and Kudo S. (1999) Oral administration of soybean lecithin transphosphatidylated phosphatidylserine (SB-tPS) reduces ischemic damage in the gerbil hippocampus. *Jpn. J. Pharmacol.* **81**, 237–239.

- Tazaki Y., Sakai F., Otomo E., Kutsuzawa T., Kameyama M., Omae T., Fujishima M. and Sakuma A. (1988) Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. *Stroke* **19**, 211–216.
- Tepper A. D., Ruurs P., Wiedmer T., Sims P. J., Borst J. and van Blitterswijk W. J. (2000) Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology. *J. Cell Biol.* **150**, 155–164.
- Thompson N. T., Bonser R. W. and Garland L. G. (1991) Receptor-coupled phospholipase D and its inhibition. *Trends Pharmacol. Sci.* **12**, 404–408.
- Thompson N. T., Garland L. G. and Bonser R. W. (1993) Phospholipase D: regulation and functional significance. *Adv. Pharmacol.* **24**, 199–238.
- Tronchere H., Record M., Terce F. and Chap H. (1994) Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. *Biochim. Biophys. Acta* **1212**, 137–151.
- Trovarelli G., de Medio G. E., Dorman R. V., Piccinin G. L., Horrocks L. A. and Porcellati G. (1981) Effect of CDP-choline on ischemia-induced alterations of brain lipid in the gerbil. *Neurochem. Res.* **6**, 821–833.
- Uchida K. and Stadtman E. R. (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. *Proc. Natl. Acad. Sci. USA* **89**, 4544–4548.
- Ulus I. H., Wurtman R. J., Mauron C. and Blusztajn J. K. (1989) Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. *Brain Res.* **484**, 217–227.
- Vance J. E. (1998) Eukaryotic lipid-biosynthetic enzymes: the same but not the same. *Trends Biochem. Sci.* **23**, 423–428.
- Vos J. P., Dehaas C. G. M., Vangolde L. M. G. and Lopescardozo M. (1997) Relationships between phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin metabolism in cultured oligodendrocytes. *J. Neurochem.* **68**, 1252–1260.
- Walkey C. J., YuL. Q., Agellon L. B. and Vance D. E. (1998) Biochemical and evolutionary significance of phospholipid methylation. *J. Biol. Chem.* **273**, 27043–27046.
- Warach S., Pettigrew L. C., Dashe J. F., Pullicino P., Lefkowitz D. M., Sabounjian L., Harnett K., Schwiderski U. and Gammans R. (2000) Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. *Ann. Neurol.* **48**, 713–722.
- Wattiaux-De Coninck S. and Wattiaux R. (1994) Ischemic effects on the structure and function of the plasma membrane, in *Subcellular Biochemistry*, Vol. 22. *Membrane Biogenesis*. (Maddy A. H. and Harris J. R., eds), pp. 361–402. Plenum press, New York.
- Weiss G. B. (1995) Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. *Life Sci.* **56**, 637–660.
- Werns S. W. and Lucchesi B. R. (1990) Free radicals and ischemic tissue injury. *Trends Pharm. Sci.* **11**, 161–166.
- White B. C., Sullivan J. M., DeGracia D. J., O'Neil B. J., Neumar R. W., Grossman L. I., Rafols J. A. and Krause G. S. (2000) Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. *J. Neurol. Sci.* **179**, 1–33.
- Wood W. G., Schroeder F., Rao A. M., Igbavboa U. and Avdulov N. A. (1996) Membranes and ethanol: lipid domains and lipid-protein interactions, in *Pharmacological Effects of Ethanol on the Nervous System*. (Deitrich R. A. and Erwin V. G. eds), pp. 13–27. CRC Press, Boca Raton.
- Wurtman R. J. (1992) Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. *Trends Neurosci.* **15**, 117–122.
- Wurtman R. J., Regan M., Ulus I. and Yu L. (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. *Biochem. Pharmacol.* **60**, 989–992.
- Yamaguchi S., Ogata H., Hamaguchi S. and Kitajima T. (1998) Superoxide radical generation and histopathological changes in hippocampal CA₁ after ischemia/reperfusion in gerbils. *Can. J. Anaes.* **45**, 226–232.
- Yen C. L. E., Mar. M. H. and Zeisel S. H. (1999) Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase. *FASEB J.* **13**, 135–142.
- Zeisel S. H. (1993) Choline phospholipids: signal transduction and carcinogenesis. *FASEB J.* **7**, 551–557.
- Zhang Y. P., Lemasters J. and Herman B. (1999) Secretory group IIA phospholipase A₂ generates anti-apoptotic survival signals in kidney fibroblasts. *J. Biol. Chem.* **274**, 27726–27733.